Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05418231
Starting soon Observational

Observation of the Natural Course of Age-related Macular Degeneration

NCT05418231 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Observational
Started
2022-07
Last updated
2022-06-14

Condition(s) studied

Dry Age-related Macular DegenerationMacular Degeneration, Dry

Study summary

This research will study natural course of dry AMD in Chinese population, screen fundus imaging indicators for patients with Chinese dry AMD, describe the clinical features of Chinese patients with dry AMD, and obtain a biological sample library of dry AMD mainly in China.

Eligibility

Sex
ALL
Min age
50 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * 50-85 yrs male or female AMD patients * Dry-AMD patients in either early, intermediate, or intermediate-to-late stage confirmed by fundus examinations. Exclusion Criteria: * Any eye with disease that would interfere with the retinal examinations * Research eye with CNV or high myopia * Surgeries that may interfere with AMD evaluation * Long-term uses of medications that are associated with retinal or neural toxicities. * IOP more than 26 mmHg * Received cataract surgery in 3 months. * Other conditions: diseases that causes less than 5 years survival; any condition that causes high risk of drop-out, or low compliance, for instance cognition disorder; have been involved in other trial that interfere with the current visit plan; taking other angiogenesis Inhibitors drugs for treating cancer. * Other conditions not suitable for the current study

Primary outcome measure(s)

  • Visual acuity — 60 months
    A typical ETDRS chart that if frequently used for visual acuity testing

Trial sites (1)

FacilityCityRegionStatus
Shanghai General Hospital, Shanghai Jiao Tong University Shanghai China

More Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials in China

Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 Recruiting
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC Recruiting
Prognostic Study of Via Dynamic Change of dT-DNA in Drainage Fluid After Radical Prostatectomy Starting soon
T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR Recruiting
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05418231 on ClinicalTrials.gov ↗ ← All trials in China